Abstract Library

#2770 Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Modica R

Authors: Modica R, Barrea L, Bottiglieri F, de Cicco F, Minotta R,

Keywords: GEP-NET, metabolic syndrome, visceral adiposity index, fatty liver index,

#2751 Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors

Introduction: Neuroendocrine tumor (NET) patients have reported ineffective communication with medical providers as a barrier to quality care.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Li D

Authors: Li D, Imbesi G, Yen L, Kim H, Sun C,

Keywords: neuroendocrine tumor, communication, doctor-patient relationship,

#1943 Neuroendocrine Tumors Committee of Reference Hospital: Evaluation of Health Care and Research Indicators

Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers which optimize results improving care and survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jimenez-Fonseca P, Vieitez J, Valdés N, Lauret M, Calvo-Temprano D,

Keywords: committee, indicator, multidisciplinary, resource,

#1721 Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR

Introduction: In advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin analogs treatment rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by Response Evaluation Criteria in Solid Tumors (RECIST) for an ‘objective response’. The implication of Stable Disease (SD) as an additional indicator of therapeutic effect is often uncertain.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luo Y

Authors: Luo Y, Chen J,

Keywords: GEP-NETs, Octreotide LAR, Progression-free Survival,

#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data

Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dromain C

Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,

Keywords: TGR, PFS,